Rational Biotechnology, Inc.

Menlo Park, CA 94025

SBIR Award Summary

Total Number of Awards 6
Total Value of Awards $2.49MM
First Award Date 05/01/06
Most Recent Award Date 05/01/10

Key Personnel

Last Name Name Awards Contact
Huang Yong Huang 6
Chen Xin Chen 1
Chen Xin Chen 0

6 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 05/01/10 - 11/30/10

DESCRIPTION (provided by applicant): Use of human primary cells (from health donors or patients) as physiology- or disease-relevant models provides significant advantages in basic research and therapeutic development for understanding and treating various human diseases, including cancer, cardiovascular and inflammatory diseases. Unfortunately, ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 09/30/09 - 03/31/11
PI: Xin Chen

DESCRIPTION (provided by applicant): RNA interference (RNAi), a biological process for modulating gene expression using short interfering RNA (siRNA) molecules, has emerged as one of the most promising technologies for treating a wide range of difficult-to-cure diseases, including liver diseases, cancer, neurodegenerative diseases, etc. However,...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 08/01/09 - 11/30/10

DESCRIPTION (provided by applicant): Use of human primary cells (from health donors or patients) as physiology- or disease-relevant models provides significant advantages in basic research and therapeutic development for understanding and treating various human diseases, including cancer, cardiovascular and inflammatory diseases. Unfortunately, ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 09/08/08 - 07/31/09

Use of human primary cells (from health donors or patients) as physiology- or disease-relevant models provides significant advantages in basic research and therapeutic development for understanding and treating various human diseases, including cancer, cardiovascular and inflammatory diseases. Unfortunately, utility of precious primary cells is ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 08/01/08 - 07/31/09

DESCRIPTION (provided by applicant): Use of human primary cells (from health donors or patients) as physiology- or disease-relevant models provides significant advantages in basic research and therapeutic development for understanding and treating various human diseases, including cancer, cardiovascular and inflammatory diseases. Unfortunately, ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/06 - 04/30/07

DESCRIPTION (provided by applicant): Human primary cells are cells directly derived from tissue samples from patients or healthy donors. They are the truest in vitro models of human physiology and disease, therefore are invaluable in medical discovery and development. Use of human primary cells as physiology- or disease-relevant models provides ...